Navana Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	10,073	8,843	6,898	5,706	4,759	3,607
Revenue Growth (YoY)	26.26%	28.19%	20.89%	19.91%	31.95%	14.53%
Cost of Revenue	5,717	4,965	3,770	3,110	2,599	1,993
Gross Profit	4,356	3,878	3,128	2,596	2,160	1,614
Selling, General & Admin	2,838	2,432	2,136	1,841	1,591	1,265
Operating Expenses	2,838	2,432	2,136	1,841	1,591	1,265
Operating Income	1,518	1,446	991.84	755.72	569.6	348.59
Interest Expense	-638.08	-726.63	-463.57	-234.89	-200.42	-75.18
Interest & Investment Income	0.36	1.07	1.47	5.84	5.58	0.03
Currency Exchange Gain (Loss)	-56.46	-54.08	-25.18	-33.38	-93.98	-2.52
Other Non Operating Income (Expenses)	6.56	6.15	11.39	-1.91	27.64	30.47
EBT Excluding Unusual Items	830.51	672.48	515.95	491.38	308.42	301.39
Gain (Loss) on Sale of Investments	-14.8	-10.46	-0.88	-42.3	82.9	-
Gain (Loss) on Sale of Assets	0.16	-0.09	1.18	-	0.47	1.02
Pretax Income	819.53	661.93	516.25	449.08	391.79	302.41
Income Tax Expense	210.49	174.12	111.62	92.14	117.78	100.12
Net Income	609.04	487.81	404.63	356.94	274	202.29
Net Income to Common	609.04	487.81	404.63	356.94	274	202.29
Net Income Growth	44.40%	20.56%	13.36%	30.27%	35.45%	47.23%
Shares Outstanding (Basic)	107	107	107	99	80	80
Shares Outstanding (Diluted)	108	107	107	99	80	80
Shares Change (YoY)	0.45%	-	8.05%	23.91%	-	-
EPS (Basic)	5.67	4.54	3.77	3.59	3.42	2.52
EPS (Diluted)	5.65	4.54	3.77	3.59	3.42	2.52
EPS Growth	43.80%	20.56%	4.92%	5.13%	35.45%	47.23%
Free Cash Flow	2,071	1,444	-625.1	-1,404	-1,160	-399
Free Cash Flow Per Share	19.19	13.44	-5.82	-14.13	-14.45	-4.97
Dividend Per Share	1.400	1.400	1.400	1.300	1.100	-
Dividend Growth	-	-	7.69%	18.18%	-	-
Gross Margin	43.25%	43.85%	45.34%	45.50%	45.39%	44.75%
Operating Margin	15.07%	16.35%	14.38%	13.24%	11.97%	9.66%
Profit Margin	6.05%	5.52%	5.87%	6.25%	5.76%	5.61%
Free Cash Flow Margin	20.55%	16.33%	-9.06%	-24.61%	-24.37%	-11.06%
EBITDA	1,804	1,715	1,163	966.13	675.37	397.71
EBITDA Margin	17.91%	19.39%	16.86%	16.93%	14.19%	11.03%
D&A For EBITDA	285.64	268.77	171.25	210.41	105.77	49.12
EBIT	1,518	1,446	991.84	755.72	569.6	348.59
EBIT Margin	15.07%	16.35%	14.38%	13.24%	11.97%	9.66%
Effective Tax Rate	25.68%	26.30%	21.62%	20.52%	30.06%	33.11%
Advertising Expenses	-	42.15	38.4	33.13	80.86	19.55

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.